Mezagitamab Biosimilar - Research Grade

Human

CD38

>1mg/ml

IgG1 - lambda

CHO Cells

Bulk Anti-Human CD38 (OKT10) Antibody (ICH1157), Daratumumab Biosimilar - Research Grade (ICH4020), Isatuximab Biosimilar - Research Grade (ICH5028), Erzotabart Biosimilar - Research Grade (ICH5533), Felzartamab Biosimilar - Research Grade (ICH5547), Lumrotatug Biosimilar - Research Grade (ICH5661)

https://www.imgt.org/mAb-DB/

ICH3002

P28907

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of mezagitamab, an anti-CD38 human IgG1/lambda monoclonal antibody, supplied strictly for research use. It is built around the CD38 target and reproduces the antigen-binding specificity of the originator molecule, making it a convenient tool for laboratory investigation rather than a clinical reagent. Researchers use it as a positive control and benchmarking reagent in CD38-directed assay development, for characterizing CD38 expression on cell lines and primary cells, for studying antibody-antigen binding kinetics, and as a reference antibody when comparing novel CD38 binders. Because it is offered in bulk milligram-to-gram quantities with low-endotoxin options (research grade below 1 EU/mg; ultra-low below 0.5 EU/mg), it also supports in-vitro functional work such as neutralization, receptor-blocking, and ADCC or antibody-drug-conjugate development pipelines, plus preclinical model characterization. It is not the clinical drug and is not intended for human or veterinary use. All content here is guidance for ichorbio to review. CD38 (UniProt P28907) is a single-pass type II transmembrane glycoprotein that acts as both a receptor and a multifunctional ectoenzyme. As an enzyme it catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and NAADP from NAD+ and NADP+, generating second messengers that regulate intracellular calcium signaling. CD38 is broadly expressed on hematopoietic cells, with particularly high levels on plasma cells, activated lymphocytes, and natural killer cells, and it functions in cell adhesion, signal transduction, and immune activation. Its consistently elevated expression on malignant plasma cells makes it a validated target in multiple myeloma and other plasma-cell and autoimmune disorders. Antibodies against CD38 can engage effector mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and phagocytosis, and may also modulate CD38 enzymatic activity, which underlies interest in CD38 as a therapeutic and research target.

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, ADPRC 1, cADPr hydrolase 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Mezagitamab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Mezagitamab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Mezagitamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Mezagitamab that binds CD38; for research use only.